US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
Blanca Blanco looks incredible in a semi
She's been turning heads during the week while attending the 77th annual Cannes Film Festival on Sun2024-05-22Twin giant panda cubs born in Madrid fine, healthy
(Xinhua) 08:37, September 08, 2021Photo taken on Sept. 6, 2021 shows the newborn panda cubs in Zoo A2024-05-22Profile: Xi Jinping Steers Decade of Reform Toward Chinese Modernization
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-22Freshman Jasen Oliver drives in 4 and Indiana holds off Purdue 8
OMAHA, Neb. (AP) — Freshman Jasen Oliver was a triple shy of a cycle and drove in four runs to lead2024-05-22(W.E. Talk) To Understand China, You Need to See China for Yourself
By Ma Jiajia & Jiang Wenqian From CNSAmerican sociologist, writer and country music singer Mark2024-05-22
atest comment